Jpmorgan Chase & CO Sellas Life Sciences Group, Inc. Transaction History
Jpmorgan Chase & CO
- $1.51 Trillion
- Q3 2025
A detailed history of Jpmorgan Chase & CO transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 40,722 shares of SLS stock, worth $61,490. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,722Holding current value
$61,490% of portfolio
0.0%Shares
9 transactions
Others Institutions Holding SLS
# of Institutions
96Shares Held
23.5MCall Options Held
1.3MPut Options Held
59.3K-
Vanguard Group Inc Valley Forge, PA6.84MShares$10.3 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.72MShares$4.1 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.2MShares$3.32 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA1.49MShares$2.25 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.13MShares$1.7 Million0.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $31M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...